Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

COMPUTATIONAL MEDICINE

Reclassifying neurodegenerative diseases

An Author Correction to this article was published on 17 September 2020

This article has been updated

Neuropathologies can be classified, on the basis of post-mortem histopathology and by using machine learning, into six transdiagnostic clusters associated with clinical phenotypes.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Clusters of neurodegenerative diseases defined by pathological features.

Change history

References

  1. Soria Lopez, J. A., Gonzalez, H. M. & Leger, G. C. Handb. Clin. Neurol. 167, 231–255 (2019).

    Article  Google Scholar 

  2. Butler, P. M. & Chiong, W. Handb. Clin. Neurol. 163, 391–410 (2019).

    Article  Google Scholar 

  3. Kovacs, G. G. Handb. Clin. Neurol. 145, 355–368 (2017).

    Article  Google Scholar 

  4. Alafuzoff, I. & Hartikainen, P. Handb. Clin. Neurol. 145, 339–353 (2017).

    Article  Google Scholar 

  5. Peng, C., Trojanowski, J. Q. & Lee, V. M. Nat. Rev. Neurol. 16, 199–212 (2020).

    Article  CAS  Google Scholar 

  6. Elahi, F. M. & Miller, B. L. Nat. Rev. Neurol. 13, 457–476 (2017).

    Article  Google Scholar 

  7. Karanth, S. et al. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2020.1741 (2020).

  8. Cornblath, E. J. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-020-0593-y (2020).

  9. Toledo, J. B. et al. Alzheimers Dement. 10, 477–484 (2014).

    Article  Google Scholar 

  10. Ransohoff, R. M. Science 353, 777–783 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pablo Villoslada.

Ethics declarations

Competing interests

P.V. owns stocks and has received consultancy fees from Accure Therapeutics, Health Engineering, QMENTA, Attune Neurosciences, CLight, NeuroPrex and Spiral Therapeutics. These companies are not associated with this work. J.C.M. has received consultancy fees from Biogen and is on their Speaker Bureau, and has received research support from AbbVie, Biogen, Esai, Eli Lilly and Company, and Novartis. R.B.-Y. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Villoslada, P., Baeza-Yates, R. & Masdeu, J.C. Reclassifying neurodegenerative diseases. Nat Biomed Eng 4, 759–760 (2020). https://doi.org/10.1038/s41551-020-0600-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41551-020-0600-3

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing